The pharmaceutical giant Merck faces yet another FDA rejection of its anesthesia drug Sugammadex, FierceBiotech reports. Sugammadex, obtained when Merck merged with the pharmaceutical company Shering-Plough, has been hailed as one of the top experimental drugs in Merck’s development pipeline. Over the years, however, it has experienced a number of setbacks, beginning with its first rejection by the FDA in 2008 and continuing with ...continue reading...
Many Americans who were diagnosed with pancreatic cancer or thyroid cancer while taking the prescription medication Byetta may wonder if they can file a Byetta lawsuit and recover for their injuries. Whether you have a claim and how much your case may be worth will depend on the specific details of your experience. You should consult with an attorney who can evaluate whether you have a viable products liability claim.
What is Byetta?
Byetta is an injectable medicine manufactured ...continue reading...
Thousands of people around the country have been injured by the prescription drug Byetta. Byetta, generically known as exanatide, is a drug used to treat type 2 diabetes. Originally manufactured by Eli Lilly and Company and Amylin Pharmaceuticals, Byetta is now manufactured by Bristol-Myers Squibb after its 2012 acquisition of Amylin. The drug is an injectable medication that can improve blood sugar control in adults who have type 2 diabetes.
Recent data has linked the use ...continue reading...
Despite many calls to action from public consumer groups, the Food and Drug Administration (FDA) has so far declined to require a recall of the drug Byetta.
What Are the Risks of Byetta?
Byetta is an injectable medicine prescribed to control the high blood sugar in millions of diabetic patients. However, medical research has shown that Byetta increases a person’s risks of the following dangerous medical conditions:
- Kidney failure;
- Pancreatic cancer; and
- Thyroid cancer.
In 2007, six Byetta-related deaths ...continue reading...
Global drug manufacturers have agreed to cooperate with an independent review of diabetes drugs classified as “incretin mimetics,” which include Byetta and Januvia, in light of a growing body of research suggesting that the drugs may be linked to pancreatic cancer and a potentially deadly inflammation of the pancreas called pancreatitis.
The American Diabetes Association has called for such a review.
A Reuters report on the issue quotes the ADA’s chief scientific and ...continue reading...
GlaxoSmithKline announced that its once-weekly diabetes drug called albiglutide was effective in late-stage clinical trials.
A story in Reuters about the announcement speculates that despite those results, the drug may face challenges in an increasingly competitive market for diabetes drugs. But some of the newer types of diabetes drugs such as Januvia and Byetta have generated health concerns recently.
The medical journal BMJ has published an investigation about the diabetes drugs called “incretin ...continue reading...